Evaluation of anti-inflammatory potential of the multidrug herbomineral formulation in male Wistar rats against rheumatoid arthritis

Snehal S. Patel, Praboth V. Shah
Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, Virgo UAP Pharma Pvt. Ltd., Sanand, Ahmedabad, Gujarat, India

ABSTRACT

Background: Immunological and inflammatory mechanisms, which may play a role in a number of disorders like rheumatoid arthritis (RA). Ancient ayurvedic physicians had developed certain dietary and therapeutic measures to arrest or prevent these disorders. Objective: Rheuma off gold (RG) is a herbomineral formulation recommended by ayurvedic medical practitioners for treatment of RA. This study was carried out to lend scientific evidence to the efficacy claim for RG in the management of RA in folklore medicine. Materials and Methods: Arthritis was induced by complete Freund’s adjuvant. Treatment with formulation 100 mg/kg and dexamethasone 2 mg/kg was given to rats intragastrically once a day from day 1 to day 21 and after which estimation of physical, biochemical, and hematological parameters were carried out. Results: Treatment of formulation to adjuvant induced arthritic animal showed statistically significant \(P < 0.05\) improvement in physical parameters like arthritic index, paw edema, paw thickness as well as reduction of inflammatory markers like C-reactive protein, serum rheumatoid factor, erythrocyte sedimentation rate. The treatment also produced statistically significant \(P < 0.05\) increase in hemoglobin percent and improvement in splenomegaly and thymus index. In the histopathological examination, ameliorative effect of formulation was observed in hyperplasia of synovium, pannus formation, and destruction of the joint space. Conclusion: The results obtained in experiments indicated that the formulation significantly inhibited the adjuvant-induced arthritis which was comparable to dexamethasone and had preferable anti-inflammatory effect without significant side effect. Thus, the formulation may be a potential preventive or therapeutic candidate for the treatment of chronic inflammation and arthritis.

Key words: Anti-inflammatory, ayurvedic, formulation, Freund’s adjuvant, immunomodulatory, rheumatoid arthritis

INTRODUCTION

Rheumatoid arthritis (RA) is the most common systematic, inflammatory, autoimmune disease, affecting 1%-1.5% of the population worldwide.\(^1\) In ayurveda “sandhivata” (sandhi = joint) term used to denote rheumatism. Ayurveda is a “codified” system of clinical science founded on basic principles with a logical superstructure. “Arthritis” means inflammation in joints, whereas “sandhivata” means vata in joints. Here, “Vata” conveys a definite theory of knowledge, based on which it can be inferred that sandhivata is a condition where pain is a characteristic clinical feature and failure of joints would possibly be its eventual dreaded result.\(^2\)

Though several drugs are available, for example, Nonsteroidal anti-inflammatory drugs (aceclofenac, diclofenac, etc.), steroids (glucocorticoid), and disease modifying antirheumatic drugs (methotrexate, cyclosporin A) for managing moderate to severe cases of arthritic pain, stiffness, and inflammation, the side effects of these drugs are often deleterious, which includes gastrointestinal irritation, cardiovascular problem, drug dependency, thymus suppression, and anemia.\(^3\) All these drawbacks of available medications have revived the interest in our traditional system of medicine. The disease preventive and health promotive approach of Ayurveda, which takes
into consideration the whole body, mind, and spirit while dealing with the maintenance of health, promotion of health and treating ailments is holistic and finds increasing acceptability in many regions of the world. Ancient ayurvedic physicians had developed certain dietary and therapeutic measures to arrest or prevent the disease like RA. In view of drawbacks of currently available synthetic drugs, it is reasoned that the pharmacological evaluation of ayurvedic proprietary formulation may combine good efficacy, absence of side effects, and could constitute a major therapeutic improvement in treatment of immunological and inflammatory disorders.

According to the ayurvedic pharmacopoeia, rheuma off gold (RG) is a herborimineral formulation believed to have the potential for providing relief to RA patients. This formulation is prepared from parts of three different plants (Commiphora mukul, Srychnos nux-vomica, Boswelia sereta), maharasnadi kwath and suvarna bhasma that are used in traditional medicine for a variety of purposes [Table 1]. However, the antiarthritic properties of this formulation not been subject to any scientifically controlled investigations so far. Investigations have, therefore, been carried out using rats as experimental models, to assess the antiarthritic potential of ayurvedic proprietary formulation in animal model of Freund’s adjuvant-induced arthritis.

**MATERIALS AND METHODS**

**Materials**

All the plants used in formulation were authenticated and formulation was prepared by Virgo UAP Pharma Pvt. Ltd. Sanand, (Ahmedabad, Gujarat, India) named as RG [Table 1] on the basis of an official ayurvedic formulation. Complete Freund’s adjuvant (CFA) was purchased from Sigma Chemicals (St. Louis, USA). C-reactive protein (CRP), serum rheumatoid factor kits were purchased from Span Diagnostics (Vadodara, India). Other chemicals used were of analytical grade.

**Experiment animals**

| Ingredients          | Botanical name                  | Part used | Composition (%) |
|----------------------|---------------------------------|-----------|-----------------|
| Mahayogaraj Guggulu  | Commiphora mukul                | Powder    | 72 mg           |
| Maharasandi kwath    | -                               | Extract   | 112 mg          |
| Suvarna bhasma       | -                               | Powder    | 1.6 mg          |
| Suddha kuchala       | Srychnos nux-vomica             | Seed      | 5.6 mg          |
| Shallaki             | Boswelia sereta                 | Exudate   | 4.8 mg          |
| Colour: Sunset yellow| -                               |           | Q.S.            |
| FCF                  | -                               |           | Q.S.            |
| Excipients           | -                               |           | Q.S.            |

FCF=For coloring food, Q.S.=Quantity sufficient

Male Wistar rats weighing 250-300 g were obtained from the animal facility of Torrent Research Centre, Gandhinagar, India. They were maintained under standard environmental conditions (12 h light/dark cycle at 20 °C temperature and 55% ± 5% controlled humidity) and provided with feed and purified water ad libitum. All experiments and protocols described in present study were approved by institutions animal ethics committee and are in accordance with guidelines as per “Guide for the care and use of laboratory animal” and with permission from Committee for the Purpose of Control and Suppression of Experiments on Animals. Animals were acclimatized for one week before starting the experiment. The pharmacological work was carried out as per approved protocol (IPS/PCOL/CONS11-12/2002).

**Experimental protocol**

Arthritis was induced by subplantar injection of 0.1 mL of CFA in left hind paw according to a method described by Newbould et al.[4] Treatment with the test compound is started on the day 1 and continued for 21 days. Rats were divided into six groups of six animals each: Normal control group, control treated with RG tablet (100 mg/kg), control treated with dexamethasone (2 mg/kg), disease control group, disease treated with RG tablet (100 mg/kg), disease treated with dexamethasone (2 mg/kg). Treatment was given to rats intragastrically once a day from day 1 to day 21 days. Paw volumes and paw thickness were recorded on the day of injection as well as 5th day and 21st day, plethysmographically. Physical parameters like body weight, arthritic index, splenomegaly, and thymus weight to body weight ratio were also measured after experimental period. Blood was collected from retroorbital plexus for measurement of biochemical and hematological parameters like serum CRP, serum rheumatoid factor, hemoglobin percent, and erythrocyte sedimentation rate as an indicative of inflammation. On day 21, rats were sacrificed and ankle joints were subjected to histopathological studies.

**Statistical analysis**

Values are expressed as mean ± standard error of the mean. The results were analyzed using one-way factorial analysis of variance followed by Tukey’s multiple comparison test using Graphpad Prism 5 software. The value of $P$ less than 5% ($P < 0.05$) was considered as statistically significant.

**RESULTS**

**Effect of formulation on physical parameters**

**Body weight**

There was gradual but statistically significant reduction in body weight observed in disease control groups, while no significant difference was observed in normal control group as well as control treated with RG tablet and dexamethzone.
Treatment with RG tablet and dexamethzone produced increase in body weight as compared to disease control group but it was not statistically significant [Figure 1a].

**Arthritic index**
Freund’s adjuvant-induced arthritic animals produced statistically significant ($P<0.05$) increase in arthritic index in disease control group as compared to normal control group. Treatment with RG tablet and dexamethasone to diseased animal showed statistically significant ($P<0.05$) reduction in arthritic score compared to disease control group. The formulation produced effect comparable to dexamethasone [Figure 1b].

**Paw volume and paw thickness**
Freund’s adjuvant-induced arthritic animals produced statistically significant ($P<0.05$) increase in paw volume and paw thickness in disease control group as compared to normal control group. Treatment with RG tablet and dexamethasone to diseased animal showed statistically significant ($P<0.05$) reduction in paw volume and paw thickness compared to disease control group. The formulation produced effect comparable to dexamethasone. While treatment with RG tablet and dexamethasone to normal animal did not showed any significant change in both the parameters [Figures 1c and d].

**Effect of formulation on secondary organ indexes**
Freund’s adjuvant-induced arthritic animals found to exhibit statistically significant ($P<0.05$) decrease in spleen and thymus index in disease control group as compared to normal control group. Treatment with formulation to diseased animal showed statistically significant ($P<0.05$) improvement in spleen and thymus index as compared to disease control group. While treatment with dexamethasone to diseased animal did not showed any protective effect on spleen and thymus index.

---

**Figure 1:** Effect of formulation on physical parameters: (a) Body weight gain, (b) arthritic index, (c) paw volume, and (d) paw thickness. Each bar represents mean ± standard error of the mean of six animals.*Significantly different from normal control ($P<0.05$), #significantly different from disease control ($P<0.05$), NC = normal control, C-TAB = Rheuma off gold Tablet (100 mg/kg), C-DEX = control treated with dexamethasone (2 mg/kg), DC = disease control group, C-TAB = disease treated with rheuma off gold tablet (100 mg/kg), D-DEX = disease treated with dexamethasone (2 mg/kg)
Treatment with formulation did not show any significant change in thymus index in normal animals, but treatment of dexamethasone to normal animal showed slight decrease in thymus index but was not statistically significant [Table 2].

**Effect of formulation RG tablet on biochemical and hematological parameters**

**C-reactive protein**
Rats treated with Freund’s adjuvant had statistically significant ($P < 0.05$) elevated levels of CRP, erythrocyte sedimentation rate, and serum rheumatoid factor in disease control group as compared to normal control group. Treatment with RG tablet and dexamethasone to diseased animal showed statistically significant ($P < 0.05$) reduction in levels of CRP, erythrocyte sedimentation rate, and serum rheumatoid factor. While treatment with RG tablet and dexamethasone to normal animal did not show any significant change in these levels [Table 3].

**Erythrocyte sedimentation rate**

**Percent hemoglobin**
Rats treated with Freund’s adjuvant had statistically significant ($P<0.05$) decreased levels of % haemoglobin (Hb) in disease control group as compared with normal control group. Treatment with RG and dexamethasone to diseased animal showed statistically significant ($P < 0.05$) increase in levels of % Hb as compared with disease control group. The formulation produced effect comparable to dexamethazone. While treatment with RG tablet and dexamethasone to normal animal did not show any significant change in levels of percent Hb as compared to normal control group [Table 3].

**Effect of formulation RG tablet on histopathology of joints**
In histopathology of ankle joints in normal control group showed normal joint structure, no cartilage destruction and no signs of inflammation or other distortion was observed. While arthritic animals showed mild to moderate hyperplasia of synovium, focal cartilage destruction, presence of pannus formation with destruction of joint space. Treatment with RG and dexamethasone group showed significant improvement in hyperplasia of synovium as compared to disease control group [Figure 2].

**DISCUSSION**

RA is a chronic inflammatory disease characterized by fibroblastic proliferation, infiltration of the synovial lining by inflammatory cells which leads to expression of proinflammatory cytokines and a paucity of apoptosis resulting in bone and joint destruction.[7] Despite enormous research being carried out for allergic and immune disease, it still remains a disorder which can be “controlled” and not “treated” since no satisfactory treatment is available in allopathic system. Hence, there is tremendous interest worldwide for the use of an alternative system of medicine. The research has been focused on formulations used in traditional medicine for treatment of RA.[8]

CFA is used to initiate induction of arthritis. This model is the original model of RA, has been extensively used to preclinical screening of new antiarthritis compounds and has successfully predicted activity in multiple new therapeutics. After a single injection of the adjuvant, a rapid, reliable, robust, and easily measurable polyarthritis develops. The joint pathology seen in this animal model shares the cartilage degradation, bone reportion, and cellular influx seen in human RA.[9,10]

In the present study, the change in body weight of rats was measured as one of the parameters to assess the course of the disease and the response to therapy of arthritic drugs.

| Parameters | NC | C-TAB | C‑DEX | DC | D-TAB | D-DEX |
|------------|----|-------|-------|----|-------|-------|
| Splenomegaly (g) | 0.09 ± 0.007 | 0.09 ± 0.007 | 0.09 ± 0.007 | 0.06 ± 0.007 | 0.07 ± 0.007 | 0.06 ± 0.007 |
| Thymus weight (g) | 0.11 ± 0.013 | 0.10 ± 0.018 | 0.10 ± 0.018 | 0.07 ± 0.004 | 0.10 ± 0.004 | 0.09 ± 0.004 |

Values are expressed as mean±standard error of the mean of six animals, *significantly different from normal control ($P < 0.05$), †significantly different from disease control ($P < 0.05$), NC=Normal control, C-TAB=RG tablet (100 mg/kg), C-DEX=Control treated with dexamethasone (2 mg/kg), DC=Disease control group, C-TAB=Disease treated with RG Tablet (100 mg/kg), D-TAB=Disease treated with dexamethasone (2 mg/kg), [analysis of variance (ANOVA) followed by Tukey’s multiple comparison test], (ANOVA followed by Tukey’s multiple comparison test).
Finding from the studies implicated that with increase the incidence and severity of arthritis, a decrease in body weight of the rats occurred during the course of the experimental period due to alterations in the metabolic activities of diseased rats. The decrease in body weight gain in the arthritic rats compared to the normal control rats in the current study is in concordance with the fact that RA is associated with loss of lean tissues, which contain most of the body’s protein. The reduction in body weight gain may also be attributed to muscle wasting in experimental arthritis, occurring due to enhanced protein breakdown by the ubiquitin-proteasome proteolytic pathway.\textsuperscript{[11,12]} It has been previously reported that decrease in the body weight during inflammation is due to deficient absorption of nutrients through the intestine.\textsuperscript{[13]} Chronic treatment with RG to arthritic rats improved loss of body weight. These effects may be attributed to either inhibition of loss of lean tissues containing body’s protein or inhibition of muscle wasting or improvement in inflammation leads to increase in absorption of nutrients through the intestine.

Arthritic index includes the combined index of inflammation, formation of nodules, and extent of spread of the disease to other organs. This gives the full picture of the disease. In chronically affected joints, the normally delicate synovium develops many villous folds because of increased numbers and size of cells in the synovial membrane and colonization by lymphocytes and plasma cells.\textsuperscript{[14]} The infiltrating cells, initially perivenular but later forming lymphoid follicles synthesize interleukin (IL)-2, cytokines, rheumatoid factor, and other immunoglobulins. Inflammation and/or nodules are observed on ears, nose, tail, fore paws, and hind paws. Arthritic index is the average of the score given to severity of the lesions in these places.
A selective reduction in the arthritis score distinguishes the immunosuppressive effects of a drug from its anti-inflammatory effects. Administration of Freund’s adjuvant-induced severe chronic disease of arthritis index in disease control group which was significantly different from normal control group. Formulation-treated group produced statistically significant reduction in arthritic score compared to disease control indicates possible immunosuppressant effect and these immunosuppressive effect may be attributed to presence of plant steroids like guggulsterones and boswellic acid in Commiphora mukul and Boswelia serata in RG which have been reported to have immunosuppressive activity.

Paw volumes and paw thickness are physical indicators of the inflammation in early as well as chronic phase of the disease. The progression of arthritis is characterized by increase of the paw footpad and tibiotalar joint diameters after day 14, which can be attributed to the delayed immunological flare in the disease. The determination of paw swelling is apparently simple, sensitive, and quick procedure for evaluating the degree of inflammation and assessing therapeutic effects of drugs. Formulation-treated group showed significant reduction in paw volume suggesting the anti-inflammatory activity of the formulation. T-cell proliferation is an important mechanism of adjuvant diseases; specifically their differentiation into Th-1 helper cells. Therefore, possible mechanism for reduction in paw edema might be either suppressive effect on Th-1 helper cells.

Splenomegaly occurs as a result of profound induction of extramedullary hematopoiesis by late-phase cytokines in the red pulp in conjunction with pyogranulomatous inflammation in the red pulp and capsule resulting in disruption of spleen histology. Administration of Freund’s adjuvant decreased spleen weight to body weight ratio in disease control groups. Spleen weight to body weight ratio was found to be increased in formulation-treated group indicating effectiveness in correcting splenomegaly. Possible mechanism may involve suppression of extramedullary hematopoiesis through action on late-phase IL-6 or IL-12.

The decrease in thymus weight is related to a suppressive effect on the immune system apart from anti-inflammatory effect. The observed decrease in thymus weights in the dexamethasone-treated normal rats was higher as compared to formulation-treated group indicates formulation have less thymus suppressive effect as compared to dexamethasone. Although in disease control group decrease in thymus weight was observed which may be due to alterations in the cell populations in these organs, which are related to the immune function. Treatment with formulation produced improvement in thymus weight. These observations indicate protective effect of formulation as compared to dexamethasone.

Adjuvant disease is associated with an increase in the plasma levels of CRP. CRP levels are closely linked to the rate of disease progression. CRP is released from liver in response to action of IL-6 in inflammatory condition and improves antigen presentation. The treatment with formulation significantly reduced the levels of CRP. The effect may be due to suppression of all stages of disease progression like inhibition of synthesis of chemical mediators because RG contains three medicinal plants (Commiphora mukul, Strychnos nux-vomica, Boswelia serata) each having proved anti-inflammatory activities. These all plants have been found to contain substances like guggulsterones, boswellic acid, and brucine, which have been proved to be anti-inflammatory by the mechanisms may be associated with the inhibition of inflammatory mediator overproduction. The formulation also contains maharasadi kwath and suvarna bhasma which is a very famous ayurvedic medicine used in vata disorders like kampavata (Parkinson’s disease), hemiplegia, paraplegia, neck pain, low back pain, RA, osteoarthritis, knee pain, and hip pain. According to the Kashaya sangrahaya and ayurveda pharmacopoeia, maharasadi kwath is a polyherbal formulation proved to be safe and nontoxic have the potential for providing relief to RA patients. This formulation is prepared from parts of 26 different plants that are used in traditional medicine for a variety of purposes such as reduction of pain, reduction of inflammation, and antipyretic activity.

Rheumatoid factor is the true marker of clinical presentation of RA. Adjuvant disease shows elevated blood levels of rheumatoid factor. Rheumatoid factor generation in arthritis involves B cell activation via toll-like receptors and several genetic predispositions to arthritic diseases. Diseased control group showed significantly elevated levels of serum rheumatoid factor compared to normal control group. The treatment with formulation significantly reduced the levels of these biomarkers of inflammation and autoimmune stimulation in the treated rats. The results of the present study indicate that the anti-inflammatory effects of formulation may be due to inhibition of activation of B cell by medicinal plants present in formulation, because all plants of formulation contains substantial amounts of plant steroids which are reported to produce anti-inflammatory action.

ESR is the indicator of chronic inflammatory disease state. Several factors which are increased in acute tissue damage, chronic inflammation, and chronic infection could have a relevant role in increased erythrocyte aggregation.
RA accompanied by raised CRP levels and CRP plays important role in the induction and maintenance of increased erythrocyte aggregation in the blood of RA patients. Treatment with formulation showed reduction in ESR. The outcomes may infer that formulation have protective effect on late-phase inflammatory markers. Thus, the reduction in the ESR brought about by treatment support its antiarthritic effect.

It is proposed that the reduction in the Hb count during arthritis results from reduced erythropoietin levels, a decreased response of the bone marrow erythropoietin and premature destruction of red blood cells. Thus, increase in the Hb count brought about by formulation further support its antiarthritic effect.

Histopathological evaluations of ankle joints in normal control group showed normal joint structure, no cartilage destruction, and no signs of inflammation or other distortion was observed. While in arthritic animals showed mild to moderate hyperplasia of synovium; focal cartilage destruction; presence of pannus formation with destruction of joint space. It also showed marked damage of articular structure indicating joint damage and inflammation. The pannus formation and bone erosion associated with inhibition of neutrophil infiltration. Hyperplastic synovial tissue (pannus) may erode cartilage, subchondral bone, articular capsule, and ligaments. Treatment with RG and dexamethasone group showed significant improvement in hyperplasia of synovium as compared to disease control group which showed protective effect of formulation on hyperplasia of synovium support its antiarthritic effect. The inhibition of pannus formation and bone erosion may be associated with inhibition of neutrophil infiltration.

Traditional medicine and medicinal plants are the powerful source of new drugs, they contributing about 90% of the newly discovered pharmaceuticals. Traditional medicine continues to provide health coverage for over 80% of the world population, especially in the developing world. Thus, on the basis of above results, it could be concluded that formulation, a combination of three herbal plants and maharasnadi kwath and suvarna bhasma exert a significant anti-inflammatory and immunosuppressive effect. This could be due to different types of active principles and different mechanism of action. However, the overall side effects like splenomegaly and thymus suppration observed with formulation are less then that with dexamethasone which could be due to different mechanism of action of individual constituent present in formulation. Therefore, combination of plants with minerals is beneficial because combination of two or more compounds with different mechanism of action may have synergetic effect or may be reducing side effect of the other constituent. Thus, it is suggested that the herbomineral formulation may be able to be considered as safe supplementary therapy for a long-term and effective management of arthritic patients.

ACKNOWLEDGMENT

This study was supported by Virgo UAP Pharma Pvt. Ltd., Ahmedabad, Gujarat, India. The authors are grateful to Virgo UAP Pharma Pvt. Ltd., for providing funds required to carry out the research work.

REFERENCES

1. Liu M, Dong J, Yang Y, Yang X, Xu H. Anti-inflammatory effects of triptolide loaded poly (D, L-lactic acid) nanoparticles on adjuvant-induced arthritis in rats. J Ethnopharmacol 2005;97:219-25.
2. Raut AA. Integrative endeavor for renaissance in Ayurveda. J Ayurveda Integr Med 2011;2:5-8.
3. Scheiman JM. The impact of nonsteroidal anti-inflammatory drug-induced gastropathy. Am J Manag Care 2001;7:S10-4.
4. Govindarajan R, Vijayakumar M, Pushpangadan P. Antioxidant approach to disease management and the role of ‘Rasayana’ herbs of Ayurveda. J Ethnopharmacol 2005;99:165-78.
5. The Ayurveda Pharmacopoeia, 2006, Part-II. Goverment of India, Ministry of health and family welfare.
6. Newbould BB. Chemotherapy of arthritis induced in rats of mycobacterial adjuvant. Br J Pharmacol Chemother 1963;21:127-36.
7. Ghidiyal S, Gautam MK, Joshi VK, Goel RK. Anti-inflammatory activity of two classical formulations of Laghupanchamula in rats. J Ayurveda Integr Med 2013;4:23-7.
8. Ram HN, Srivastava NK, Mahija IK, Shreedhara CS. Anti-inflammatory activity of Ajmodidi Churna extract against acute inflammation in rats. J Ayurveda Integr Med 2012;3:33-7.
9. Andersen ML, Santos EH, Seabra Mde L, da Silva AA, Tufik S. Evaluation of acute and chronic treatments with Harpagophyllum procumbens on Freund’s adjuvant-induced arthritis in rats. J Ethnopharmacol 2004;91:325-30.
10. Bendele A, McComb J, Gould T, McAbee T, Sennello G, Chipala E, et al. Animal models of arthritis: Relevance to human disease. Toxicol Pathol 1999;27:134-42.
11. Lecker SH. Ubiquitin-protein ligases in muscle wasting: Multiple parallel pathways? Curr Opin Clin Nutr Metab Care 2003;6:271-5.
12. Granado M, Priego T, Martin AI, Villanua MA, Lopez-Calderon A. The ghrelin receptor agonist GHRP-2, prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscle. Am J Physiol Endocrinol Metab 2005;289:E1007-14.
13. Patil KR, Patil CR, Jadhav RB, Mahajan VK, Patil PR, Gaikwad PS. Anti-Arthritic activity of bartogenic acid isolated from fruits of Barringtonia racemosa Roxb. (Lecythidaceae). Evid Based Complement Alternat Med 2011;2011:785245.
14. Bello AE, Desser S. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: A review of the literature. Curr Med Res Opin 2006;22:2221-32.
15. Yu Y, Xiong Z, Lv Y, Qian Y, Jiang S, Tian Y. In vivo evaluation of early disease progression by X-ray phase-contrast imaging in the adjuvant-induced arthritic rat. Skeletal Radiol 2006;35:156-64.
16. Knaus U, Wagner H. Effects of boswellic acid of Boswelia serrata and other triterpenic acids on the complement system. Phytomedicine 1996;3:77-80.
17. Gebhard C, Stämpfl S, Gebhard C, Akhmedov A, Breitenstein A, Camici GG, et al. Guggulsterone, an anti-inflammatory phytoestrogen, inhibits tissue factor and arterial thrombosis. Basic Res Cardiol 2009;104:285-94.

18. Duwieuia M, Zeitlin IJ, Waterman PG, Chapman J, Mhango GJ, Provan GJ. Anti-inflammatory activity of resins from some species of the plant family Burseraceae. Planta Med 1993;59:12-6.

19. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secerting Th3 regulatory cells. Immunol Rev 2001;182:207-14.

20. Campbell I, Bendele A, Smith DA, Hamilton JA. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis 1997;56:364-8.

21. Verhof CM, van Roon JA, Vianen ME, Lafeber FP, Bijlsma JW. The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. Ann Rheum Dis 1999;58:49-54.

22. Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, et al. Simultaneous development of acute phase response and auto antibodies in preclinical rheumatoid arthritis. Ann Rheum Dis 2006;65:535-7.

23. Otterness IG. The value of C-reactive protein measurement in rheumatoid arthritis. Semin Arthritis Rheum 1994;24:91-104.

24. Ammon HP, Mack T, Singh GB, Safayhi H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata. Planta Med 1991;57:203-7.

25. Yin W, Wang TS, Yin FZ, Cai BC. Analgesic and anti-inflammatory properties of brucine and brucine N-oxide extracted from seeds of Strychnos nux-vomica. J Ethnopharmacol 2003;88:205-14.

26. Sosa S, Tubaro A, Loggia RD, Bombardelli E. Anti-inflammatory activity of Commiphora mukul extracts. Pharmacol Res 1993;27:89-90.

27. Thabrew MI, Dharmasiri MG, Senaratna L. Anti-inflammatory and analgesic activity in the polyherbal formulation Maharasnadi Quathar. J Ethnopharmacol 2003;85:281-7.

28. Thabrew MI, Senaratna L, Samarawickrema N, Munasinghe C. Antioxidant potential of two polyherbal preparations used in Ayurveda for the treatment of rheumatoid arthritis. J Ethnopharmacol 2001;76:285-91.

29. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.

30. Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol 2004;16:246-53.

31. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7.

32. Hopstaken RM, Muris JW, Kootnerus JA, Kester AD, Rinkens PE, Dinant GJ. Contributions of symptoms, signs, erythrocyte sedimentation rate, and C-reactive protein to a diagnosis of pneumonia in acute lower respiratory tract infection. Br J Gen Pract 2003;53:358-64.

33. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7.

34. Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR. Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in adjuvantinduced arthritis in female albino rat: An isobolographic study. Eur J Pharmacol 2007;556:190-9.

35. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 2012;209:925-33.

How to cite this article: Patel SS, Shah PV. Evaluation of anti-inflammatory potential of the multidrug herbomineral formulation in male Wistar rats against rheumatoid arthritis. J Ayurveda Integr Med 2013;4:86-93.

Source of Support: Virgo UAP Pharma Pvt. Ltd., Conflict of Interest: None declared.